An extracellular humanized IFNAR immunocompetent mouse model for analyses of human interferon alpha and subtypes

References

• Isaacs A, Lindenmann J. Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957. J Interferon Res. 1987 Oct;7(5):429–438.
   PubMedGoogle Scholar
• Gonzalez-Navajas JM, Lee J, David M, et al. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012;12(2):125–135. doi:10.1038/nri3133
   PubMed Web of Science ®Google Scholar
• Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol. 2015;15(4):231–242. doi:10.1038/nri3806
   PubMed Web of Science ®Google Scholar
• Hoffmann HH, Schneider WM, Rice CM. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol. 2015;36(3):124–138. doi:10.1016/j.it.2015.01.004
   PubMed Web of Science ®Google Scholar
• Lavoie TB, Kalie E, Crisafulli-Cabatu S, et al. Binding and activity of all human alpha interferon subtypes. Cytokine. 2011;56(2):282–289. doi:10.1016/j.cyto.2011.07.019
   PubMed Web of Science ®Google Scholar
• Chen J, Li Y, Lai F, et al. Functional comparison of interferon-α subtypes reveals potent hepatitis B virus suppression by a concerted action of interferon-α and interferon-γ signaling. Hepatology. 2021;73(2):486–502. doi:10.1002/hep.31282
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Wu PC, et al. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet. 1988;2(8606):298–302.
   PubMed Web of Science ®Google Scholar
• Ye J, Chen J. Interferon and hepatitis B: current and future perspectives. Front Immunol. 2021;12:733364, doi:10.3389/fimmu.2021.733364
   PubMed Web of Science ®Google Scholar
• Moini M, Fung S. HBsAg loss as a treatment endpoint for chronic HBV infection: HBV cure. Viruses. 2022 Mar 22;14(4):657.
   PubMed Web of Science ®Google Scholar
• Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827–844. doi:10.1038/s41573-019-0037-0
   PubMed Web of Science ®Google Scholar
• Harari D, Abramovich R, Zozulya A, et al. Bridging the species divide: transgenic mice humanized for type-I interferon response. PLoS One. 2014;9(1):e84259, doi:10.1371/journal.pone.0084259
   PubMed Web of Science ®Google Scholar
• Lavender KJ, Gibbert K, Peterson KE, et al. Interferon alpha subtype-specific suppression of HIV-1 infection in vivo. J Virol. 2016;90(13):6001–6013. doi:10.1128/JVI.00451-16
   PubMed Web of Science ®Google Scholar
• Haymaker CL, Hailemichael Y, Yang Y, et al. In vivo assay for detection of antigen-specific T-cell cytolytic function using a vaccination model. J Vis Exp. 2017;129.
   Google Scholar
• Saletti G, Cuburu N, Yang JS, et al. Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Nat Protoc. 2013;8(6):1073–1087. doi:10.1038/nprot.2013.058
   PubMed Web of Science ®Google Scholar
• Schuhenn J, Meister TL, Todt D, et al. Differential interferon-alpha subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection. Proc Natl Acad Sci USA. 2022;119(8).
   Web of Science ®Google Scholar
• Le Bon A, Etchart N, Rossmann C, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol. 2003;4(10):1009–1015. doi:10.1038/ni978
   PubMed Web of Science ®Google Scholar
• Uchida T, Imamura M, Hayes CN, et al. Persistent loss of hepatitis B virus markers in serum without cellular immunity by combination of peginterferon and entecavir therapy in humanized mice. Antimicrob Agents Chemother. 2017;61(9).
   Web of Science ®Google Scholar
• Coulstock E, Sosabowski J, Ovecka M, et al. Liver-targeting of interferon-alpha with tissue-specific domain antibodies. PLoS One. 2013;8(2):e57263, doi:10.1371/journal.pone.0057263
   PubMed Web of Science ®Google Scholar
• Song J, Li S, Zhou Y, et al. Different antiviral effects of IFNα subtypes in a mouse model of HBV infection. Sci Rep. 2017;7(1):334, doi:10.1038/s41598-017-00469-1
   PubMedGoogle Scholar
• Zhao W, Lee C, Piganis R, et al. A conserved IFN-α receptor tyrosine motif directs the biological response to type I IFNs. J Immunol. 2008;180(8):5483–5489. doi:10.4049/jimmunol.180.8.5483
   PubMed Web of Science ®Google Scholar
• Krause CD, Pestka S. Cut, copy, move, delete: the study of human interferon genes reveal multiple mechanisms underlying their evolution in amniotes. Cytokine. 2015;76(2):480–495. doi:10.1016/j.cyto.2015.07.019
   PubMed Web of Science ®Google Scholar
• Cardenas JJ, Robles-Oteiza C, Politi K. Assessment of IFNgamma responsiveness in patient-derived xenografts. Methods Enzymol. 2020;631:415–427. doi:10.1016/bs.mie.2019.10.027
   PubMed Web of Science ®Google Scholar
• Politi K. Leveraging patient-derived models for immunotherapy research. Am Soc Clin Oncol Educ Book. 2020;40:e344–e350.
   PubMedGoogle Scholar
• Rongvaux A, Willinger T, Martinek J, et al. Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol. 2014;32(4):364–372. doi:10.1038/nbt.2858
   PubMed Web of Science ®Google Scholar
• Sutter K, Dickow J, Dittmer U. Interferon α subtypes in HIV infection. Cytokine Growth Factor Rev. 2018;40:13–18. doi:10.1016/j.cytogfr.2018.02.002
   PubMed Web of Science ®Google Scholar
• Meng CY, Sun S, Liang Y, et al. Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance. Gut. 2023;72(8):1544–1554. doi:10.1136/gutjnl-2022-327059
   PubMed Web of Science ®Google Scholar
• Xia Y, Schlapschy M, Morath V, et al. PASylated interferon α efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice. Antiviral Res. 2019;161:134–143. doi:10.1016/j.antiviral.2018.11.003
   PubMed Web of Science ®Google Scholar
• Hotz C, Wagenaar TR, Gieseke F, et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med. 2021;13(610):eabc7804, doi:10.1126/scitranslmed.abc7804
   PubMed Web of Science ®Google Scholar
• Administration FaD. Reviews for BLA 103964, pegylated interferon alfa 2a (Pegasys) https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103964. 2002.
   Google Scholar
• Zanin N, de Lesegno C V, Lamaze C, et al. Interferon receptor trafficking and signaling: journey to the cross roads. Front Immunol. 2020;11:615603.
   PubMed Web of Science ®Google Scholar